MercachemSyncom involved in development of second-generation AhR inhibitors
MercachemSyncom has been selected by Hercules Pharmaceutical B.V., as the chemical partner for their project on second-generation AhR inhibitors.
How our novel, scalable route efficiently led to a crucial GMP intermediate
The so-called three component Povarov reaction was used to prepare a tetrahydroquinoline from an aniline, an aldehyde and an enamine. This reaction had been reported before in literature but this was the first time it was applied to synthesize an API.
MercachemSyncom announces organizational changes
MercachemSyncom is pleased to announce several changes in its organization to position the company for the next phase of growth and development.
MERCACHEMSYNCOM OPENS USA OFFICE IN CAMBRIDGE, MA
We are excited to tell you that this month we celebrated the opening of our first office in the USA at the Cambridge Innovation Center (CIC) at One Broadway, Cambridge, MA. The office will be managed by Dr. Bart DeCorte, Vice President of Business Development for North America.
Bionetix, ProQinase, and MercachemSyncom announce a joint research project from target Identification to clinical study
Bionetix announced they have signed a joint multiyear integrated drug-discovery project, starting from target identification (TI) up to clinical candidate selection on an undisclosed target aimed at acute myeloid leukemia (AML).
MercachemSyncom closes acquisition of Alcami Weert
It is our great pleasure to announce today that MercachemSyncom has acquired Alcami’s European cGMP CMC drug substance development site, based in Weert, the Netherlands.
